These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 17163577)
1. Continuous Bayesian adaptive randomization based on event times with covariates by Cheung et al., Statistics in Medicine 2006; 25:55-70. Chappell R; Karrison T Stat Med; 2007 Jul; 26(15):3050-2; author reply 3052-4. PubMed ID: 17163577 [No Abstract] [Full Text] [Related]
2. Continuous Bayesian adaptive randomization based on event times with covariates. Cheung YK; Inoue LY; Wathen JK; Thall PF Stat Med; 2006 Jan; 25(1):55-70. PubMed ID: 16025549 [TBL] [Abstract][Full Text] [Related]
4. Predicting event times in clinical trials when randomization is masked and blocked. Donovan JM; Elliott MR; Heitjan DF Clin Trials; 2007; 4(5):481-90. PubMed ID: 17942464 [TBL] [Abstract][Full Text] [Related]
5. Constructing intervals for the intracluster correlation coefficient using Bayesian modelling, and application in cluster randomized trials. Turner RM; Omar RZ; Thompson SG Stat Med; 2006 May; 25(9):1443-56. PubMed ID: 16220510 [TBL] [Abstract][Full Text] [Related]
6. The distribution of loss in two-treatment biased-coin designs. Atkinson AC Biostatistics; 2003 Apr; 4(2):179-93. PubMed ID: 12925515 [TBL] [Abstract][Full Text] [Related]
8. Weibull prediction of event times in clinical trials. Ying GS; Heitjan DF Pharm Stat; 2008; 7(2):107-20. PubMed ID: 17377932 [TBL] [Abstract][Full Text] [Related]
9. Predicting analysis times in randomized clinical trials. Bagiella E; Heitjan DF Stat Med; 2001 Jul; 20(14):2055-63. PubMed ID: 11439420 [TBL] [Abstract][Full Text] [Related]
10. Predicting event times in clinical trials when treatment arm is masked. Donovan JM; Elliott MR; Heitjan DF J Biopharm Stat; 2006 May; 16(3):343-56. PubMed ID: 16724489 [TBL] [Abstract][Full Text] [Related]
11. Re: "use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection". van Noord PA; van der Tweel I Am J Epidemiol; 2005 Nov; 162(10):1033-5. PubMed ID: 16221807 [No Abstract] [Full Text] [Related]
12. An orwellian discourse on the meaning and measurement of noninferiority. Diamond GA; Kaul S Am J Cardiol; 2007 Jan; 99(2):284-7. PubMed ID: 17223435 [TBL] [Abstract][Full Text] [Related]
13. Single patient (n-of-1) trials with binary treatment preference. Schluter PJ; Ware RS Stat Med; 2005 Sep; 24(17):2625-36. PubMed ID: 16118811 [TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trials in implant therapy: relationships among methodological, statistical, clinical, paratextual features and number of citations. Nieri M; Clauser C; Franceschi D; Pagliaro U; Saletta D; Pini-Prato G Clin Oral Implants Res; 2007 Aug; 18(4):419-31. PubMed ID: 17517060 [TBL] [Abstract][Full Text] [Related]
15. A pattern-mixture model for the analysis of censored quality-of-life data. Li H; Heitjan DF Stat Med; 2006 May; 25(9):1533-46. PubMed ID: 16435338 [TBL] [Abstract][Full Text] [Related]
16. Predicting analysis time in event-driven clinical trials with event-reporting lag. Wang J; Ke C; Jiang Q; Zhang C; Snapinn S Stat Med; 2012 Apr; 31(9):801-11. PubMed ID: 22344853 [TBL] [Abstract][Full Text] [Related]
17. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods. Jordan P; Brunschwig H; Luedin E Pharm Stat; 2008; 7(1):36-41. PubMed ID: 17335108 [TBL] [Abstract][Full Text] [Related]